2016
DOI: 10.1530/joe-16-0142
|View full text |Cite
|
Sign up to set email alerts
|

Metformin increases hepatic leptin receptor and decreases steatosis in mice

Abstract: In addition to the ascertained efficacy as antidiabetic drug, metformin is increasingly being used as weight-loss agent in obesity, and as insulin sensitizer in nonalcoholic fatty liver disease (NAFLD). However, the mechanisms underlying these effects are still incompletely understood. Emerging evidence suggest metformin as leptin sensitizer to mediate the weight-loss effect in the brain. In this study, we investigated effects of metformin on expression of leptin receptors in liver and kidney in mice. C57BL/6 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

5
38
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 52 publications
(44 citation statements)
references
References 68 publications
5
38
0
1
Order By: Relevance
“…Interestingly, the upregulation of leptin receptors through fasting exerts pronounced antipro-liferative effects on lymphoblastic leukemia cells (33). Metformin, a mimetic of caloric restriction (14) and the most common antihyperglycemia agent used to treat type 2 diabetes mellitus, reduces leptin serum concentrations and increases the level of OBR mRNA in the liver, but not the kidney, of mice (50); that is, different cells and organs exhibit distinct responses to alterations in leptin concentration.…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, the upregulation of leptin receptors through fasting exerts pronounced antipro-liferative effects on lymphoblastic leukemia cells (33). Metformin, a mimetic of caloric restriction (14) and the most common antihyperglycemia agent used to treat type 2 diabetes mellitus, reduces leptin serum concentrations and increases the level of OBR mRNA in the liver, but not the kidney, of mice (50); that is, different cells and organs exhibit distinct responses to alterations in leptin concentration.…”
Section: Discussionmentioning
confidence: 99%
“…Metformin (MET) has been used as the first‐line drug therapy for T2DM, due to its excellent inhibitory effect on hepatic glucose production . Berberine (BB) is an isoquinoline alkaloid originally isolated from Chinese herb Coptis chinensis (Huang lian), which exerts anti‐diabetic and anti‐inflammatory activities .…”
Section: Introductionmentioning
confidence: 99%
“…Metformin (MET) has been used as the first-line drug therapy for T2DM, due to its excellent inhibitory effect on hepatic glucose production. [10][11][12] Berberine (BB) is an isoquinoline alkaloid originally isolated from Chinese herb Coptis chinensis (Huang lian), which exerts anti-diabetic [13][14][15][16] and anti-inflammatory activities. [17][18][19] Over the past decades, a number of experimental and clinical studies have been centralized on the biological activities of Metformin, Berberin and their derivatives.…”
mentioning
confidence: 99%
“…46,47,51 Although potentially beneficial changes in glycogen metabolism were detected in metformin-treated OE-NPY DbH mice, glucose tolerance was not markedly improved, which is not unexpected in glucose-tolerant mice. 54 In conclusion, this study shows that the overall glycogen metabolism and the content of stabile fraction are increased in a prediabetic OE-NPY DbH model even preceding IGT and glycogen accumulation, and may thus contribute to the progression of the disease, or to NPY-induced metabolic disruptions. Metformin significantly changes the structure of glycogen especially by diminishing the content of uncomplete stabile fraction, and suppresses both glycogen synthesis and phosphorylation.…”
Section: Discussionmentioning
confidence: 61%
“…Although potentially beneficial changes in glycogen metabolism were detected in metformin‐treated OE‐NPY DβH mice, glucose tolerance was not markedly improved, which is not unexpected in glucose‐tolerant mice . Instead, metformin‐treated WT mice displayed mild improvement in glucose tolerance, possibly due to decreased visceral adiposity, as no response in glycogen structure was detected.…”
Section: Discussionmentioning
confidence: 87%